Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

Leukemia volume 17, pages 1925–1929 (2003)Cite this article

Abstract

Interphase fluorescence in situ hybridization (I-FISH) for the BCR-ABL translocation performed on peripheral blood (PB) white cells has been suggested as a surrogate for conventional bone marrow (BM) cytogenetics for monitoring patients with chronic myeloid leukemia (CML). I-FISH is faster, less costly, and does not require BM aspiration. For patients treated with interferon-alpha (IFN), a good correlation between the two methods has been demonstrated in several though not all studies. However, imatinib mesylate (STI571) has largely replaced IFN as the standard drug treatment for CML, raising the question if the results obtained in IFN-treated patients are applicable to patients on imatinib. We therefore compared the two methods in patients on imatinib and patients on other therapies, mainly IFN (collectively referred to as nonimatinib therapies). Our results demonstrate that the correlation between I-FISH and cytogenetics is much weaker in patients on imatinib than in patients on nonimatinib therapies. Correction of the I-FISH values for the proportion of lymphocytes barely improved the correlation, probably as a result of unpredictable proportions of Philadelphia-positive B cells. By contrast, I-FISH of PB neutrophils was much better correlated with BM cytogenetics. We conclude that I-FISH on unselected PB white cells is not suitable for monitoring patients on imatinib.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.

    CAS  PubMed  Google Scholar 

  2. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

    Article  CAS  PubMed  Google Scholar 

  3. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU . Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532–538.

    Article  CAS  PubMed  Google Scholar 

  4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541–1548.

  5. Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Loffler H et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. Bone Marrow Transplant 1996; 17 (Suppl. 3): S21–S24.

    PubMed  Google Scholar 

  6. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  PubMed  Google Scholar 

  7. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177–2187.

    CAS  PubMed  Google Scholar 

  8. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  PubMed  Google Scholar 

  9. Tbakhi A, Pettay J, Sreenan JJ, Abdel-Razeq H, Kalaycio M, Hoeltge G et al. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders. Am J Clin Pathol 1998; 109: 16–23.

    Article  CAS  PubMed  Google Scholar 

  10. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J et al. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res 1998; 4: 861–867.

    CAS  PubMed  Google Scholar 

  11. Yanagi M, Shinjo K, Takeshita A, Tobita T, Yano K, Kobayashi M et al. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 1999; 13: 542–552.

    Article  CAS  PubMed  Google Scholar 

  12. Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998; 21: 90–100.

    Article  CAS  PubMed  Google Scholar 

  13. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59.

    Article  CAS  PubMed  Google Scholar 

  14. Faderl S, Kantarjian HM, Talpaz M, O'Brien S . New treatment approaches for chronic myelogenous leukemia. Semin Oncol 2000; 27: 578–586.

    CAS  PubMed  Google Scholar 

  15. Lesser ML, Dewald GW, Sison CP, Silver RT . Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet 2002; 137: 79–84.

    Article  CAS  PubMed  Google Scholar 

  16. Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000; 18: 1533–1538.

    Article  CAS  PubMed  Google Scholar 

  17. Seong D, Kantarjian HM, Albitar M, Arlinghaus R, Xu J, Talpaz M et al. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol 1999; 10: 955–959.

    Article  CAS  PubMed  Google Scholar 

  18. Deininger M, Lehmann T, Krahl R, Hennig E, Muller C, Niederwieser D . No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. Blood 2000; 96: 779–780.

    CAS  PubMed  Google Scholar 

  19. Takahashi N, Miura I, Saitoh K, Miura AB . Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758–4763.

    CAS  PubMed  Google Scholar 

  20. Froncillo MC, Maffei L, Cantonetti M, Del Poeta G, Lentini R, Bruno A et al. FISH analysis for CML monitoring? Ann Hematol 1996; 73: 113–119.

    Article  CAS  PubMed  Google Scholar 

  21. Cox-Froncillo MC, Cantonetti M, Masi M, Lentini R, Giudiceandrea P, Maffei L et al. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. Cancer Genet Cytogenet 1995; 84: 15–18.

    Article  CAS  PubMed  Google Scholar 

  22. Nolte M, Werner M, Ewig M, von Wasielewski R, Wilkens L, Link H et al. Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. Leukemia Lymphoma 1996; 22: 287–294.

    Article  CAS  PubMed  Google Scholar 

  23. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064–4077.

    CAS  PubMed  Google Scholar 

  24. Sinclair PB, Green AR, Grace C, Nacheva EP . Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 1395–1402.

    CAS  PubMed  Google Scholar 

  25. Sick C, Schultheis B, Pasternak G, Kottke I, Horner S, Heissig B et al. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization. Ann Hematol 2001; 80: 9–16.

    Article  CAS  PubMed  Google Scholar 

  26. Garicochea B, Chase A, Lazaridou A, Goldman JM . T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. Leukemia 1994; 8: 1197–1201.

    CAS  PubMed  Google Scholar 

  27. Eibl B, Ebner S, Duba C, Bock G, Romani N, Erdel M et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997; 20: 215–223.

    Article  CAS  PubMed  Google Scholar 

  28. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM . Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929–1936.

    CAS  PubMed  Google Scholar 

  29. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549–1555.

    CAS  PubMed  Google Scholar 

  30. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579–1583.

    Article  CAS  PubMed  Google Scholar 

  31. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE . Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771–777.

    Article  CAS  PubMed  Google Scholar 

  32. Wang L, Pearson K, Ferguson JE, Clark RE . The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003; 120: 990–999.

    Article  CAS  PubMed  Google Scholar 

  33. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9: 160–166.

    CAS  PubMed  Google Scholar 

  34. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  PubMed  Google Scholar 

  35. Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF et al. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica 2002; 87: 979–988.

    CAS  PubMed  Google Scholar 

  36. Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Haifa-Kathrin Al-Ali for dedicated patient care. We are grateful to Ms Christel Müller, Ms Christina Franke and Ms Daniela Klug for excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of Hematology, University of Leipzig, Germany

    U Reinhold, E Hennig, S Leiblein, D Niederwieser & M W N Deininger

  2. BMT/Leukemia, Oregon Health and Science University, Portland, OR, USA

    M W N Deininger

Authors
  1. U Reinhold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Hennig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Leiblein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M W N Deininger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reinhold, U., Hennig, E., Leiblein, S. et al. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia 17, 1925–1929 (2003). https://doi.org/10.1038/sj.leu.2403077

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403077

Keywords

This article is cited by

Search

Advanced search

Quick links